Oncoinvent ASA: Invitation to Result Presentation Q4 2024

Oslo, Norway 20, February 2025In connection with the release of the results for the full year and fourthquarter 2024, Oncoinvent invites to the following events:Thursday 27 February 202507.30 CETRelease of stock exchange notification. Press release, quarterly report andpresentation will be available on www.oncoinvent.com.10.00 CETLive streamed of quarterly presentation in English. A webcast will beavailablefor everyone to view on www.oncoinvent.com. There will be a possibility forQ&Athrough the MS Teams Webinar.About OncoinventOncoinvent is a clinical-stage biotechnology company developing novelradiopharmaceutical therapies against cancer. The lead product candidate,Radspherin, uses the alpha-emitting radionuclide radium-224, directlytargetingmicro-metastases post-surgery, harnessing the benefits of modernradiopharmaceuticals without the complexities of biological targeting.Oncoinvent is investigating the safety and efficacy of Radspherin in aclinicaldevelopment program in two indications. Currently two phase 1/2a trials andonerandomized phase 2 trial are ongoing in the US, UK and Europe. More than 150patients with peritoneal carcinomatosis, secondary to ovarian and colorectalcancer, will be enrolled in the current program. Preliminary clinical efficacydata are highly encouraging, and no serious toxicity or safety concerns havebeen reported to date. The Oncoinvent team consists of approx. 30 employeesandruns a state-of-the-art manufacturing facility to produce drug products forclinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext GrowthOslo.Forward-Looking StatementsAll statements other than statements of historical facts contained in thispressrelease are forward-looking statements and are not a representation thatOncoinvent's plans, estimates, or expectations will be achieved. Theseforward-looking statements represent Oncoinvent's expectations as of the dateofthis press release, and Oncoinvent disclaims any obligation to update theforward-looking statements. These forward-looking statements are subject toknown and unknown risks and uncertainties that may cause actual results todiffer materially, including with respect to whether the results of clinicalorother studies will support the use of our product offerings, the impact ofresults of such studies, our expectations of the reliability, accuracy andperformance of our tests, or of the benefits of our tests and productofferingsto patients, providers and payers.For further information, please contact:Øystein Soug, Chief Executive OfficerEmail: [email protected] Kvam, Chief Financial Officer Email: [email protected]://newsweb.oslobors.no/message/639225